MARAbio

Executive Summary

MARAbio is a precision immunology company pioneering the identification and management of Maternal Autoantibody Related Autism (MARA), a distinct biological subtype of autism spectrum disorder. The company has developed a proprietary blood test that detects specific autoantibodies in maternal serum, which have been shown to predict the likelihood of MARA in a child. This test addresses a critical unmet need in autism diagnostics, moving beyond behavioral assessments toward early, objective biological screening. By identifying at-risk children prenatally or shortly after birth, MARAbio's approach enables earlier intervention and personalized treatment strategies. The company's long-term vision extends to developing targeted therapeutics that modulate the maternal autoantibody response, potentially mitigating or preventing the neurodevelopmental consequences of MARA. With its headquarters in San Diego, MARAbio is positioned at the intersection of immunology and neurodevelopment, offering a paradigm shift in how autism is diagnosed and managed. The company's innovative diagnostic platform has the potential to impact millions of families by providing actionable insights during critical windows of neurodevelopment. As the field moves toward precision medicine in psychiatry, MARAbio's focus on a biologically defined subtype represents a significant advancement, with implications for clinical trial design, treatment response prediction, and ultimately improved outcomes for children with MARA.

Upcoming Catalysts (preview)

• Q3 2026Publication of clinical validation study for MARA blood test70% success
• Q4 2026Partnership with major diagnostic lab or pharmaceutical company50% success
• Q1 2027FDA breakthrough device designation or initial regulatory submission40% success